Northern Institute for Cancer Research

Staff Profile

Dr Carmela Ciardullo

Research Associate

Background

Qualifications

2008: BSc Biological Sciences (110/110 cum laude), University of Calabria – Italy

2011: MSc Biological Sciences (110/110 cum laude), University of Calabria – Italy

2015: PhD Clinical and Experimental Medicine (Hematology), Amedeo Avogadro University of Eastern Piedmont, Novara – Italy

 

Previous Positions

May 2015-April 2016: Research Fellow, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK


Memberships

European Hematology Association (EHA)

British Society for Haematology (BSH)

American Society of Hematology (ASH)

American Association for Cancer Research (AACR)


Languages

English, Italian

    

Research

  • Ex vivo treatment of resting and CD40L-stimulated primary chronic lymphocytic leukaemia samples with second-generation MDM2 inhibitors

  • Assessment of gene expression signature of p53 target genes in response to second-generation MDM2 inhibitors in primary chronic lymphocytic leukaemia samples

  • Isolation, culture and ex vivo treatment of normal mature blood cells and CD34+ haematopoietic stem cells to assess the effect of non-genotoxic p53 reactivation via MDM2 inhibition

  • Analysis of Next Generation sequencing data to assess the mutational status of TP53 gene in primary chronic lymphocytic leukaemia samples in different disease stage


  • Expression analysis of the death-associated kinase DRAK2 in patient-derived chronic lymphocytic leukaemia samples and correlation with disease outcome

  • Development of a siRNA knockdown assay to assess the function of the death-associated kinase DRAK2 in a panel of B-cell lines

  • Expression analysis of the transcription factors BACH2 and BCL6 in patient-derived chronic lymphocytic leukaemia samples and correlation with disease outcome


  • Mutational analysis of primary leukaemia and lymphoma samples in different stages of disease

  • Development of amplicon-based Next Generation Sequencing approaches to identify subclonal TP53, NOTCH1, SF3B1 and BIRC3 mutations in chronic lymphocytic leukaemia

  • Development of Next Generation Sequencing and bioinformatics approaches to identify mutations in circulating tumour DNA isolated from patients with B-cell lymphomas

Publications